Report Overview

North America osteoporosis treatment market is growing owing to demand which is being fueled in North America by the rising incidence of osteoporosis and the increasing number of therapeutic drug approvals.

North America Osteoporosis Treatment Market - Industry Trends & Forecast Report 2028

North America osteoporosis treatment market was worth USD 6.27 billion in 2021 and is further projected to reach USD 10.25 billion by the year 2028, registering a CAGR of 7.5% during 2022-2028 (forecast period). The rapid expansion of the market is predominantly due to the bone loss and increased susceptibility to fracture characterize osteoporosis, which develops as bone density decreases over time. This typically occurs in middle life or later, and females are three to four times more likely to be affected than males. An estimated 1.66 million hip fractures occur annually worldwide due to osteoporosis, according to the World Health Organization. About 54 million Americans have osteoporosis, per the National Osteoporosis Foundation.

North America Osteoporosis Treatment Market - Overview

Osteoporosis increases the risk of fracture, particularly in the spine and wrists, due to low bone mass and tissue deterioration. The success of providers in treating the disease depends on the discovery of more targeted treatments, such as anabolic drugs. Taking an anabolic steroid can help you build bone mass, increase your bone density, and decrease the frequency with which you break a bone. Many drugs with different mechanisms of action have been approved for the prevention and treatment of osteoporosis, are effective and available worldwide. These treatmentsmust be used in conjunction with calcium and vitamin D supplements, recommended lifestyle changes, adequate nutrition and physical activity.

Companies such as Amgen Inc. and Astellas Pharma Inc. are currently working on producing a bone-forming monoclonal antibody for the treatment medicament, in addition to the anabolic agents developed by Radium Health Inc. for the treatment of osteoporosis in postmenopausal women and osteoporosis associated with prolonged systemic glucocorticoid therapy, both of which have been licensed by the U.S. Food and Drug Administration (FDA). The demand for osteoporosis treatmentsis expected to rise in the forecast period, thanks in part to the clearance of new treatments and the presence of a promising drug pipeline.

North America Osteoporosis Treatment Market Forecast and Trends

Growth Drivers

Increase in Clinical Trials and the Development of More Effective Diagnostic Tools to Propel the Market Growth

The market is being driven by the rise in the manufacturing of innovative treatmentsand the rise in awareness concerning the treatment and diagnosis of the osteoporosis condition. This, in addition to the growing attention paid to the issue of unmet needs for osteoporosis therapy in underdeveloped countries, is a constant driver of new product launches by the industry's leading competitors. Some firms, for instance, are analyzing the treatments pipeline for osteoporosis from the perspective of the method of administration. The silent aspect of the disease that gradually weakens bones over time is linked to low levels of patient compliance. As a result, the introduction of transdermal patches for the delivery of osteoporosis drugs is a primary focus of manufacturers. For instance, Teijin Pharma is in the midst of phase II studies for a transdermal patch called abaloparatide.

In addition, Zosano Pharma is working on a teriparatide-delivering microneedle patch. Consequently, it is expected that the introduction of such innovative products to drive the development of new methods of drug administration, resulting in increased compliance rates and enhanced quality of care for osteoporosis patients. Apart from this, new effective diagnostic solutions for screening for osteoporosis have been introduced as a result of increasing technological advancements. For instance, Bone Index Finland Ltd. has released bindex, a tool for diagnosing osteoporosis in accordance with international standards. This device is useful for high-volume screening of high-risk groups because of its accuracy, ease of use, and speed. Because of this, there has been a rise in the number of people undergoing treatment for osteoporosis because more people are being diagnosed with the condition.

Market Expansion is Expected to be Fueled by the High Prevalence of Osteoporosis Disease Around the World

The market expansion for osteoporosis treatments is commonly attributed to an increase in the prevalence of osteoporotic fractures such as hip and vertebral fractures among postmenopausal women. Patients over the age of 65, postmenopausal women, those with a parathyroid hormone abnormality, and men at high risk of fractures are the groups most likely to experience osteoporosis. Thus, the International Osteoporosis Foundation predicts that one in three women and one in five males over the age of 50 is expected to suffer a fracture due to osteoporosis

Also, in the year 2000, there were close to 9 million newly reported cases of osteoporotic fractures; among them, 1.6 million were hip fractures, 1.7 million were forearm fractures, and 1.4 million were vertebral fractures. Demand for treatments to treat osteoporosis is expected to rise as a result of these rising numbers. For example, the National Osteoporosis Foundation estimates that 10 million Americans, 65 million Europeans, and 34 million Japanese are living with osteoporosis or osteopenia (low bone mass). Manufacturers are responding to the rising demand for their products around the world by investing more resources into R&D. Therefore, this would help drive the demand for osteoporosis treatments.

Market Restraint 

The Market for Osteoporosis Drugs is Being Held Back by their Potentially Harmful Side Effects and Increased Risk

A rise in healthcare awareness, an increase in women's health maintenance, and an increase in new product launches by manufacturers to strengthen market share are some of the factors that would restrain the market's expansion during the forecast period, despite the fact that the market has grown over the years due to an increase in the incidence of osteoporosis conditions.

Drug patent expiration due to rising risk factors, negative drug effects, and other causes are stymieing development. Market expansion is being stymied by such factors as anti-inflammatory medications' unfavorable side effects and the lack of conclusive proof demonstrating the product's efficacy. Hot flashes, vomiting, leg cramps, change in bowel habits, diarrhea, and other side effects of osteoporotic medicines are frequently a problem. In addition, constraints such as strict restrictions, prolonged FDA clearances, product recalls, and others may slow the market's expansion.

Impact of COVID-19 on North America Osteoporosis Treatment Market

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the WHO declaring it a public health emergency. The global impacts of the COVID-19 are already starting to be felt. The COVID-19 pandemic has led to the healthcare systems and hospitals to divert their complete focus on treating people suffering from the disease. In contrast, several elective medical procedures and osteoporosis treatment appointments have either been cancelled or postponed. During 2020, the North America osteoporosis treatment market had exhibited a slow growth due to the aforementioned reasons; however, the market returned to normalcy in 2021.

Segmental Coverage 

North America Osteoporosis Treatment Market – By Drug Class

Bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators (SERMs), rank ligand inhibitors (RANKL), and others make up the drug class-based osteoporosis market. As the standard of care for treating osteoporosis, bisphosphonates are driving industry expansion. Bisphosphonate-containing medications, by reducing osteoclast activity, also aid in halting bone loss. As a result, they reduce bone loss by boosting bone strength and bone density. The introduction of new products that provide greater results in a shorter amount of time is also contributing to the expansion of the market. Alendronate (Fosamax) and risedronate (Actonel) are two such drugs that are used on a regular basis. While Reclast is used only once yearly, osteoporosis treatment is ongoing.

Increases in the frequency of growth hormone deficits in key nations, rising demand for treatment areas that are safe and effective compared to others, and other factors are likely to propel the hormone replacement therapy medicines segment to the greatest CAGR throughout the forecast period. Parathyroid hormone is also extensively utilized for people with multiple fractures because it stimulates cells that build new bones.

North America Osteoporosis Treatment Market – Route of Administration

The market for drugs used to treat osteoporosis is segmented into two major types, oral and parenteral. Since parenteral medicines are increasingly used to treat osteoporosis, this administration method is seen as the market leader. In addition, the rising demand for the parenteral medicine is leading to more of it being manufactured, which is helping the market expand. However, new biosimilars that are easier to use and pose no health risks to patients taking them orally are expected to boost that market segment significantly throughout the projection period.

Competitive Landscape

Competition in the North American market is becoming more aggressive as major corporations work with smaller ones to broaden their product lines and increase sales. Growth in the North American market is further encouraged by the fact that other major companies are using both organic and inorganic growth tactics, including collaboration, the launch of new products, and mergers and acquisitions.

More and more investment is being made into R&D by major players in the North America osteoporosis treatment market in order to produce cutting-edge products and remain competitive. Decision-makers need to keep up with market trends and drivers if they want to seize this new opening. The report details the evolving nature of the investment landscape in the North American osteoporosis treatment industry, as well as the market's current state, future outlook, and potential revenue generators.

Recent Developments

• A potential biosimilar to Stelara called AVT04 (ustekinumab) received positive topline findings from two separate studies in May 2022: one was a confirmatory clinical, safety, and effectiveness trial, and the other was a pharmacokinetic (PK) study. Alvotech made the announcement.

• In July 2022, a global biotech company that specializes in the development and manufacture of biosimilar medicines for patients all over the world, made an announcement that they have begun a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia and Xgeva. This study will evaluate the drug's ability to perform in a manner that is comparable to Prolia and Xgeva. In this phase of the clinical research, healthy adult male participants will be used to evaluate the pharmacokinetics, safety, and tolerability of AVT03 in comparison to Prolia.

Scope of the Report

By Drug class

• Bisphosphonate
• Hormone Replacement Therapy
• Selective Estrogen Receptor Modulator
• Rank Ligand Inhibitor
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Country

• U.S.
• Canada